GlassScriptPhysician profile
Traesa A Brown
NPI 1053407973
$1,574.92
in general payments reported to CMS, 2019-2025
29 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $345 · 2021: $191 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $240.08 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $235.45 | 2019-2025 | Breztri |
| Astellas Pharma US INC | $178.67 | 2019 | |
| Pfizer INC. | $106.66 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $95.75 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $69.57 | 2025 | Rexulti |
| Novo Nordisk INC | $46.44 | 2021-2025 | Wegovy |
| Horizon Therapeutics Plc | $44.45 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.35 | 2019-2021 | |
| Mannkind Corporation | $37.42 | 2019 | |
| Amarin Pharma, INC. | $33.06 | 2019 | |
| Mylan Specialty L.P. | $31.82 | 2019-2020 | |
| Shire North American Group INC | $31.57 | 2019 | |
| Abbvie INC. | $29.25 | 2020-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $28.03 | 2025 | Loreev Xr, Teriparatide |
| Sanofi-Aventis U.S. LLC | $26.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.58 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.43 | 2025 | Caplyta |
| Mission Pharmacal Company | $23.54 | 2019 | |
| Exact Sciences Corporation | $18.98 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $15.74 | 2025 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $15.29 | 2025 | Auvelity |
| Eisai INC. | $14.69 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2021 | |
| Genentech USA, INC. | $13.78 | 2019 | |
| Hikma Pharmaceuticals USA | $13.10 | 2019 | |
| Abbott Laboratories | $12.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traesa Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.